Literature DB >> 11760786

Expression, specificity and immunotherapy potential of prostate-associated genes in murine cell lines.

M E Grossmann1, M Wood, E Celis.   

Abstract

The TRAMP-C1 (C1) and TRAMP-C2 (C2) cell lines were derived from a prostate tumor that arose in a mouse from the transgenic adenocarcinoma mouse prostate (TRAMP) model. However, their similarity to primary prostate tumors and therefore their usefulness in immunotherapy studies has not been clearly defined. We showed using RT-PCR that these cell lines exhibited a variety of prostate-specific genes expressed by human prostate tumors that may be used as tumor-associated antigens for immunotherapy. Interestingly, several of these genes are also expressed in cell lines that are not prostatic in origin. The prostate cell lines were also shown to grow in an androgen-independent manner, to be capable of expressing MHC class I and to be susceptible to specific lysis by cytotoxic T lymphocytes. Therefore, these cell lines will provide us with the ability to evaluate immune responses to and tolerance of prostate-specific protein peptides in an animal model.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11760786     DOI: 10.1007/pl00007104

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  6 in total

1.  Oncolytic herpes simplex virus armed with xenogeneic homologue of prostatic acid phosphatase enhances antitumor efficacy in prostate cancer.

Authors:  P Castelo-Branco; B J Passer; J S Buhrman; S Antoszczyk; M Marinelli; C Zaupa; S D Rabkin; R L Martuza
Journal:  Gene Ther       Date:  2010-03-11       Impact factor: 5.250

2.  Obstructing shedding of the immunostimulatory MHC class I chain-related gene B prevents tumor formation.

Authors:  Jennifer D Wu; Catherine L Atteridge; Xuanjun Wang; Tsukasa Seya; Stephen R Plymate
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

3.  SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade.

Authors:  Marcella Fassò; Rebecca Waitz; Yafei Hou; Tae Rim; Norman M Greenberg; Nilabh Shastri; Lawrence Fong; James P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-26       Impact factor: 11.205

4.  Cutting edge: permissive MHC class II allele changes the pattern of antitumor immune response resulting in failure of tumor rejection.

Authors:  Elena N Klyushnenkova; Diana V Kouiavskaia; Carla A Berard; Richard B Alexander
Journal:  J Immunol       Date:  2009-02-01       Impact factor: 5.422

5.  Prostate stem cell antigen DNA vaccination breaks tolerance to self-antigen and inhibits prostate cancer growth.

Authors:  Sarfraz Ahmad; Garrett Casey; Paul Sweeney; Mark Tangney; Gerald C O'Sullivan
Journal:  Mol Ther       Date:  2009-03-31       Impact factor: 11.454

6.  Oncogenic mechanisms of HOXB13 missense mutations in prostate carcinogenesis.

Authors:  Marta Cardoso; Sofia Maia; Paula Paulo; Manuel R Teixeira
Journal:  Oncoscience       Date:  2016-10-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.